The Shuman Law Firm Investigates Geron Corp.

BOULDER, Colo.--()--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Geron Corp. (“Geron” or the “Company”) (Nasdaq: GERN). Geron is a Menlo Park, CA-based clinical stage biopharmaceutical company.

The Firm’s investigation relates to allegations raised in a class action lawsuit against the Company concerning the Company’s drug, imetelstat, and related clinical trials which took place between June 16, 2013 and March 11, 2014. The class action alleges that Geron's senior officers and directors may have known that patients treated with imetelstat exhibited liver function abnormalities putting them at risk for chronic liver injury but nonetheless made statements to the public that imetelstat was safe and well-tolerated. When the Food and Drug Administration (FDA) suspended imetelstat clinical trials on March 11, 2014 due to these liver toxicity concerns, Geron's stock fell 62%.

The Firm is investigating whether Geron's officers' and directors' statements may have exposed the Company to civil liability. The Company currently faces a class action lawsuit alleging that Geron knew about imetelstat's harmful side effects and concealed these facts from the public. On April 10, 2015, U.S. District Judge Charles R. Breyer denied, in part, Geron's motion to dismiss the class action and the case is proceeding toward trial.

If you currently own Geron common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 569-4531 or email Mr. Shuman at or email Mr. Glenn at

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.


The Shuman Law Firm
Kip B. Shuman, Esq., 303-861-3003
Rusty E. Glenn, Esq., 303-861-3003
Toll-Free: 866-569-4531
Fax: 303-536-7849

Recent Stories

RSS feed for The Shuman Law Firm


The Shuman Law Firm